Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87
Seagen hasn't let a pending acquisition by Pfizer interrupt its business development activities, adding to its pipeline with a wide-ranging partnership with Nurix Therapeu
Astellas has become the latest big pharma to pledge big bucks to a smaller company working on protein degraders, paying $35 million upfront to partner with US start-up Cul
Proxygen has added another big pharma company to its list of partners, with Merck & Co the latest to be snared by its molecular glue degrader technology.
Gilead Sciences clearly liked what it saw in the early stages of its 2019 partnership with Nurix on protein degradation drugs – it has just opted into the first of five po
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho